Stem cell therapy for chronic liver disease—choosing the right tools for the job

Forbes, Stuart J.
February 2008
Gut;Feb2008, Vol. 57 Issue 2, p153
Academic Journal
The author reflects on the need for newer strategies that could efficiently treat advanced liver diseases. He attributes the need to the increasing rate of mortality among cirrhosis patients due to shortages in organ donors. He also considers the potential of bone marrow stem cells to regenerate liver stem cells for a cirrhotic liver. Based on clinical results, he states that mesenchymal stem cells can have advantages and disadvantages when applied to damaged live organs.


Related Articles

  • Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR. Imahashi, N; Suzuki, R; Fukuda, T; Kakihana, K; Kanamori, H; Eto, T; Mori, T; Kobayashi, N; Iwato, K; Sakura, T; Ikegame, K; Kurokawa, M; Kondo, T; Iida, H; Sakamaki, H; Tanaka, J; Kawa, K; Morishima, Y; Atsuta, Y; Miyamura, K // Bone Marrow Transplantation;Jan2013, Vol. 48 Issue 1, p56 

    Allogeneic hematopoietic SCT (allo-HCT) from matched sibling donor (MSD) is recommended for younger patients with intermediate cytogenetic risk AML in first CR (CR1), whereas the role of alternative donor transplants in these patients is unknown. We retrospectively analyzed 605 patients with...

  • 23. Selected Aspects.  // Bone Marrow Transplantation;3/2/2002 Supplement, Vol. 29 Issue 5, pS237 

    Bone Marrow Transplantation (2001) 29, Suppl. 2, S237–S240. DOI: 10.1038/sj/bmt/1703492

  • Partial CD8+T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Ho, V. T.; Kim, H. T.; Li, S.; Hochberg, E. P.; Cutler, C.; Lee, S. J.; Fisher, D. C.; Milford, E.; Kao, G.; Daley, H.; Levin, J.; Ng, A.; Mauch, P.; Alyea, E. P.; Antin, J. H.; Soiffer, R. J. // Bone Marrow Transplantation;Dec2004, Vol. 34 Issue 11, p987 

    Summary:Prior studies suggest that depletion of CD8+T cells from donor bone marrow or donor lymphocyte infusions can reduce graft-versus-host disease (GVHD) without compromising graft-versus-leukemia. We explored CD8 depletion in patients undergoing matched related donor (MRD, n=25) and...

  • Non-TBI stem cell transplantation protocol for Fanconi anaemia using HLA-compatible sibling and unrelated donors. Fuente, J. De La; Reiss, S.; M. Mecloy; Vulliamy, T.; Roberts, Jag; Rahemtulla, A.; Dokal, I. // Bone Marrow Transplantation;Jul2004, Vol. 34 Issue 1, p95 

    CORRECTION TO:: Bone Marrow Transplantation (2003) 32, 653-656. doi:10.1038/sj.bmt.1704219On page 654, right-hand column, first paragraph, the following sentence was published incorrectly and should read as follows:Secondly, in addition to CSA, for GVHD prophylaxis, patients received Campath-1H...

  • Family donor care management: principles and recommendations. van Walraven, S. M.; Nicoloso-de Faveri, G.; Axdorph-Nygell, U. A. I.; Douglas, K. W.; Jones, D. A.; Lee, S. J.; Pulsipher, M.; Ritchie, L.; Halter, J.; Shaw, B. E. // Bone Marrow Transplantation;Aug2010, Vol. 45 Issue 8, p1269 

    The World Marrow Donor Association (WMDA) is an international organization fostering collaboration in clinical transplantation and promoting the interests of unrelated stem cell donors. The WMDA has developed standards for the recruitment, counseling, work-up and subsequent donations to protect...

  • Encephalopathy in pediatric patients after allogeneic hematopoietic stem cell transplantation is associated with a poor prognosis. Woodard, P.; Helton, K.; McDaniel, H.; Khan, R. B.; Thompson, S.; Hale, G.; Benaim, E.; Kasow, K.; Leung, W.; Horwitz, E.; Srivastava, D. K.; Tong, X.; Yusuf, U.; Cunningham, J. M.; Handgretinger, R. // Bone Marrow Transplantation;Jun2004, Vol. 33 Issue 11, p1151 

    Encephalopathy is a poorly characterized complication of hematopoietic stem cell transplantation (HSCT). No comprehensive report of encephalopathy exists for children, and the literature contains only a few for adults. We analyzed a large cohort of 405 pediatric patients who underwent allogeneic...

  • Comorbidity indices in hematopoietic stem cell transplantation: a new report card. Alamo, J.; Shahjahan, M.; Lazarus, H. M.; de Lima, M.; Giralt, S. A. // Bone Marrow Transplantation;Sep2005, Vol. 36 Issue 6, p475 

    Summary:Comorbid conditions have not been studied systematically for impact upon patient outcome in the setting of hematopoietic stem cell transplantation (HSCT). Patients formerly excluded from myeloablative transplant due to comorbid illnesses now receive reduced-intensity conditioning...

  • Prediction of duration and success rate of unrelated hematopoietic stem cell donor searches based on the patient's HLA-DRB1 allele and DRB1-DQB1 haplotype frequencies. Hirv, K.; Bloch, K.; Fischer, M.; Einsiedler, B.; Schrezenmeier, H.; Mytilineos, J. // Bone Marrow Transplantation;Oct2009, Vol. 44 Issue 7, p433 

    Rapid identification of a matched unrelated donor is essential for patients in need of hematopoietic SCT. We carried out a retrospective evaluation of 549 unrelated donor searches (UDSs), which were completed in 2005 for 23 German transplant centers. On the basis of the patient's HLA-DRB1 allele...

  • Análise Sociodemográfica e Clínica de Pacientes Submetidos ao Transplante Alogênico de Células-Troncos Hematopoiéticas. Nogueira Guimarães de ABREU, Mauro Henrique; de OLIVEIRA, Igor Rafael; Gonçalves RESENDE, Renata; Mendes de Matos CARDOSO, Natália; de Fátima CORREIA-SILVA, Jeane; GOMEZ, Ricardo Santiago // Pesquisa Brasileira em Odontopediatria e Clinica Integrada;jul-set2012, Vol. 12 Issue 3, p345 

    Objective: To describe the clinical and sociodemographic findings of the patients subjected to hematopoietic stem cell transplantation (HSCT) and referred to the School of Dentistry of the Federal University of Minas Gerais (FO-UFMG). Method: Thirty-nine pre-allogeneic HSCT patients were...


Read the Article


Sign out of this library

Other Topics